Najar, Hemen
Karanti, Alina
Pålsson, Erik
Landén, Mikael
Funding for this research was provided by:
Vetenskapsrådet (2022-01643)
Hjärnfonden (FO2022-0217)
The Swedish Government under the LUA/ALF agreement (ALFGBG-965444)
University of Gothenburg
Article History
Received: 9 February 2023
Accepted: 26 March 2023
First Online: 3 April 2023
Declarations
:
: The study was approved by the regional ethical review board in Stockholm, Sweden (registration code: 2008/1931.32). All participants consented orally and in writing after being presented with detailed information about the study.
: Mikael Landén declares that he has received lecture honoraria from Lundbeck pharmaceuticals and has served as consultant for AstraZeneca. No other author has any conflict of interest to declare.